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Introduction
The health burden of Heart Failure with Preserved Ejection 
Fraction (HFpEF) is substantial. In some countries, HFpEF is the 
leading cause of hospital admission in patients over 65 years of 
age and is predicted to be the leading cause of mortality within a 
decade [1,2]. HFpEF is characterised by reduced exercise capacity 
and ability to engage in activities of daily living, poor Health-
Related Quality of Life (HRQoL), high rates of hospitalisation, 
and premature mortality [3]. In sharp contrast to the wealth of 
proven therapies for Heart Failure with Reduced Ejection Fraction 
(HFrEF) that have improved mortality and morbidity, there is a 
distinct lack of treatment options for HFpEF. Drugs or devices 
which are recommended in current HF treatment guidelines to 
improve outcomes in HFrEF have not been shown to have similar 
benefit in HFpEF patients, and to date, phase III randomised 
controlled trials have not consistently yielded evidence-based 
therapy for HFpEF [4]. The lack of treatment options in patients 
with HFpEF represents a significant unmet need that urgently 
demand new therapeutic strategies that arguably target mechanisms 
specific for HFpEF.
Targeting co-morbidities in HFpEF
A key feature of HFpEF patients is the presence of several 
comorbidities, including obesity, diabetes and hypertension, 
that contribute not only to the aetiology of HFpEF but also to 
the progression of the disease in HFpEF [5-7]. A new paradigm 
on the relationship between comorbidities and the development 
of HFpEF has been proposed [8]. This hypothesised that the 
high prevalence of comorbidities in HFpEF synergistically 
induces a systemic pro-inflammatory state, leading to coronary 
microvascular and generalized endothelial inflammation, which in 
turn results in abnormalities in ventricular and vascular function 
ultimately leading to increased Left Ventricular Hypertrophy 
(LVH), diastolic dysfunction due to LV stiffness and consequent 
HFpEF development. Indeed, patients with HFpEF have evidence 
of inflammation not only in the myocardium but also in lungs, 
skeletal muscles, and kidneys that contributes to pulmonary 
hypertension, exercise intolerance, and renal impairment in 
HFpEF [9,10]. In the BIOSTAT study, we recently confirmed 
the importance of inflammation in HFpEF patients in a network 
analysis of 92 biomarkers in patients with HFpEF [11]. These 
observations support the notion that targeting comorbidities and 
the consequent systemic microcirculatory dysfunction may be a 
strategic approach in addressing the unmet therapeutic needs of 
HFpEF [12].
Obesity, metabolic syndrome, insulin resistance, diabetes and 
HFpEF
There are several lines of evidence strongly suggesting 
that obesity and diabetes contributes to the risk of developing 
and worsening HFpEF [13]. Obesity is highly prevalent (50%) in 
HFpEF patients [12]. In patients with HFpEF, Body Mass Index 
(BMI) is strongly associated with New York Heart Association 
(NYHA) functional class and a predictor of poor outcome [14,15]. 
It is likely that obesity is more than just a co-morbidity for HFpEF 
and instead may be involved in its pathogenesis. Obesity has been 
identified as a risk factor for HFpEF [16,17]. Increased adiposity 
promotes hypertension, systemic inflammation and insulin 
resistance, all of which are commonly observed in patients with 
HFpEF [18]. Obesity also impairs cardiac, vascular, and skeletal 
muscle function [19]. Adipose tissue is metabolically active and 
produces cardiovascular active substances such as inflammatory 
cytokines and adipokines. In addition, increased visceral adiposity 
on multi-slice imaging has been shown to be associated with a 
higher risk of HFpEF events [20].
With respect to diabetes and HFpEF, there is evidence 
suggesting that there are two distinct Heart Failure (HF) 
phenotypes associated with diabetic cardiomyopathy. The first is 
of Type 1 Diabetes (T1D) that leads to HFrEF with a dilated left 
ventricular phenotype and the second is of Type 2 Diabetes (T2D) 
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associated with obesity that leads to a HFpEF phenotype with 
concentric remodelling of the Left Ventricle (LV) [21]. Seferović 
and Paulus recently presented evidence attributing the aetiology 
of the two phenotypes to the differential principal involvement 
of either microvascular endothelial cells (HFpEF) or cardiac 
myocytes (HFrEF) in the remodelling process [22]. In post-hoc 
analyses of both the I-PRESERVE trial as well as in CHARM-
Preserved, HFpEF patients with T2D had more fluid congestion 
and worse quality of life and prognosis [23,24]. Thus, obesity and 
diabetes are not only risk factors for the development of HFpEF 
but also have a significant impact on its symptoms and outcome. 
Obesity and T2D (or diabesity) are therefore attractive potential 
therapeutic targets in HFpEF. Supportive evidence that obesity 
contributes to exercise intolerance in HFpEF through systemic 
inflammation has come from a 20-week caloric restriction diet 
in obese HFpEF that demonstrated an improvement in peak VO2 
that strongly correlated with reduced body fat mass and hs-CRP, a 
biomarker of inflammation [25].
Targeting Obesity in HFpEF 
Recognising the importance of comorbidities (that include 
obesity and insulin resistance), our collaborator, CSL and key 
investigators in the field have proposed six plausible mechanisms 
of potential translational significance: 3 haemodynamic 
mechanisms (left atrial hypertension, pulmonary hypertension, 
and volume overload) and 3 cellular/molecular mechanisms 
(microvascular inflammation, cardio-metabolic abnormalities, 
and cellular/extracellular structural changes) [3]. The first three 
haemodynamic mechanisms (left atrial hypertension, pulmonary 
hypertension, and volume overload) are currently being targeted 
with devices (interatrial septal device) and drugs in on going trials 
with endothelin antagonists, guanylate cyclase modulators, ARNI 
(in the PARAGON study) and SGLT2 inhibitors (EMPEROR-
PRESERVED) [3,26] Of note, inter-atrial septal device 
intervention that reduces Pulmonary Capillary Wedge Pressure 
(PCWP) was shown to be safe and potentially beneficial at 1-year 
although its impact on hard outcomes remains unclear [27,28]. 
We also recognise the intense interest around SGLT2 inhibitors in 
HFpEF with at least 2 multi-centre international trials exploring 
this, EMPEROR-PRESERVED (with empagliflozin) and 
PRESERVED-HF (with dapagliflozin). However, we believe that 
there is a need to explore other potential therapeutic interventions. 
In this respect, the diabetic drug, metformin, may have potential in 
the setting of HFpEF.
Metformin and Its Potential in HFpEF
There are plausible reasons why metformin may be 
useful in HFpEF (Figure 1). Systemic inflammation is a key 
pathophysiological process in many of the comorbidities associated 
with HFpEF. There is evidence that metformin may have anti-
inflammatory effects. In a translational study, we have shown 
that metformin inhibited tumour necrosis factor-α–dependent IκB 
degradation and the expression of pro-inflammatory mediators’ 
interleukin-6, interleukin-1β, and CXCL1/2 in primary hepatocytes 
of healthy animals [29]. These in-vitro findings were validated in 
a large population cohort study of treatment naïve T2D patients 
and also in a subset of non-diabetic HF patients from a double 
blind randomized controlled trial [29]. Second, metformin has 
the potential to regress the adverse ventricular remodelling in 
non-diabetic patients with coronary artery disease as observed in 
the MET-REMODEL trial, a consistent finding with preclinical 
evidence [30]. Third, metformin’s ability to reduce weight is a 
consideration for its potential therapeutic benefits in HFpEF. In 
the MET-REMODEL trial, metformin reduced weight (by 4 kg), 
a consistent finding with metformin use [30] . This reduction in 
weight could be beneficial in HFpEF. Fourth, metformin can also 
reduce blood pressure that could also potentially benefit HFpEF. 
Fifth, a recent study reported that metformin offers therapeutic 
benefit in mice models with HFpEF–like phenotype by reducing 
LV diastolic stiffness, an effect explained by metformin induced 
reduction in titin-based passive stiffness [31]. Finally, metformin 
has also been shown to improve pulmonary hypertension related to 
HFpEF, at least in animal models [32,33]. Although metformin has 
not been examined in patients with HFpEF, It is noteworthy that in 
patients with HFrEF and insulin resistance, metformin improved 
the VE/VCO2 slope in patients with HFrEF and insulin resistance 
[34]. In that study, there was also a non-statistical marginal 
reduction of NTproBNP in the metformin arm. 
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Figure 1: Plausible reasons why Metformin may be useful in HFpEF.
Taking into account all of the above therapeutic benefits 
observed in clinical and preclinical studies, it is clear that there 
is a need to explore the magnitude of the pleotropic effects of 
metformin, particularly in patients with HFpEF. Future studies 
exploring the beneficial effects of metformin in HFpEF patients 
are warranted (https://clinicaltrials.gov/ct2/show/NCT03629340).
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